EBITDA

Beyond the ad break: How TripleLift's focus on creative formats, global retail media partnerships, and AI is disrupting the programmatic advertising landscape.

A third-generation family takeover, backed by Canada's BDC, positions a 70-year-old firm to accelerate innovation in the competitive medical imaging market.

With leadership buying shares and promising trial data for its novel cancer drug, MAIA Biotechnology is sending strong signals to investors. What's next?

Ghost Robotics' new arm gives its Vision 60 the power to act. This leap from seeing to doing has huge implications for industries from defense to healthcare.

How TerraVest's aggressive acquisition spree is reshaping industrial markets and delivering substantial returns to shareholders. Dive into the strategy.

A breakthrough genetic therapy for ALS offers hope, but a split verdict from Canadian health agencies reveals the tough calculus of innovation versus cost.

Promising interim data for a Parkinson's vaccine sends AC Immune's stock soaring, signaling a potential paradigm shift from symptom management to disease modification.

Lindsay Corp.'s massive irrigation project in MENA isn't just a sale; it's a strategic move in the high-stakes race to solve global food security.

With AI-guided drills and a new discovery, Nevada King aims to transform its Atlanta mine into a major US gold asset. Will the market take notice?

The U.S. Coast Guard taps AeroVironment for advanced underwater robots, a key step in its Force Design 2028 plan to boost safety and mission efficiency.

Bristol Myers Squibb's Opdivo gets FDA priority review, backed by landmark data suggesting it could unseat a key competitor as the new gold standard.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

Beyond the hype, one company's dual leadership award reveals the true engine of the GenAI revolution: a smarter, more powerful search foundation.

Biotech startup Bio Usawa appoints a world-renowned health expert to lead its access board, betting its entire business model on making advanced drugs affordable.

A landmark UK study reveals an AI diagnostic tool that predicts heart attacks with stunning accuracy and offers a £25 million lifeline to strained health budgets.

Bill Ackman's fund posted a stellar 24.1% return. We dive into the high-conviction plays and innovative structure driving this market-beating performance.

OMRON's new global ECG strategy leverages AI and key acquisitions to tackle heart disease, aiming to eliminate adverse cardiovascular events.

The industrial giant secured a rare dual 'A' rating from CDP. We decode what this means for its strategy, competitors, and ESG-focused investors.

A new 8MWh energy storage system in Matsusaka showcases how advanced technology is helping Japan balance industrial power with its green energy ambitions.

A rival bid reshaped a major gold merger, creating a West African powerhouse. Here’s how the deal was saved and what it means for the market.